|

Chimeric Antigen Receptor T cells (CAR-T) Targeting BCMA Clinical Trials

1 actively recruiting trial across 1 location

Also known as: CAR-T Infusion

Pipeline

Phase 1: 1

Top Sponsors

  • Thomas Martin, MD1

Indications

  • Recurrent Multiple Myeloma1
  • Refractory Multiple Myeloma1
  • Multiple Myeloma1
  • Cancer1

San Francisco, California1 trial

CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma

University of California, San Francisco

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.